Author:
Pagoria Dustin,O’Connor R. Corey,Guralnick Michael L.
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.
2. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2–6.
3. Sigala S, Mirabella G, Peroni A, Pezzotti G, Simeone C, Spano P, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology. 2002;60(4):719–25.
4. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol. 2003;43(1):1–5.
5. •• Wiedemann A, Schwantes PA. Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same?—a comparative review of data pertaining to pharmacological and physiological aspects. Euro J Ger. 2007; 9 (suppl 1):29–42. This is an excellent review of the mechanisms of action of antimuscarinics at the muscarinic receptors and adverse CNS effects.
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献